



# 台灣生醫材料公司(6649)法人說明會

2022/12/12

# Disclaimer

- The information contained in this confidential document (“Presentation”) has been prepared by Taiwan Biomaterial Co., Ltd. (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers gives, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision or supplement thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers takes any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness or injury of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation or the information.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved by the Company to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed “forward-looking statements”. All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, general economic, market or business conditions and other unforeseen events. Prospective Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.

# 公司基本資料

## ■產品項目

人工腦膜、腦中風治療導管系統及其他高階醫療器材

## ■技術來源：工業技術研究院

## ■公司設立時間：2012年11月12日

## ■公司地點：竹北生醫園區

## ■資本額：新台幣4.2億元

## ■董事長：林志茂

## ■總經理：王文熙

## ■員工人數：34人



# 商業模式

## Transforming Clinical Concept to Medical Product



臨床需求

台灣生醫材料

國際品牌合作夥伴

聚焦於**臨床需求到產品上市之價值創造**



# 創新產品pipeline

與矽谷夥伴共同合作開發



台生材自主研發




# 合併綜合損益表

單位:新台幣千元

	2022年1~3季		2021年1~3季		年成長
營業收入	81,375	100%	34,902	100%	133%
營業成本	23,480	29%	7,530	22%	
營業毛利	57,894	71%	27,369	78%	112%
營業費用	51,269	63%	68,793	197%	
營業利益(損失)	6,625	8%	(41,424)	-119%	
營業外收支	11,381	14%	9,392	27%	
稅前淨利(損)	18,006	22%	(32,032)	(92%)	
本期淨利(損)	18,006	22%	(32,032)	(92%)	由虧轉盈
基本每股盈餘 (NTD)	0.44		(0.97)		





# 季營收額

單位:新台幣千元



# 人工腦膜修復產品

Remove the dura mater during neurosurgery




全球人工腦膜市場總值**4.8億美元**

**臨床需求:** 腦膜修補及防止腦脊髓液滲漏




# 泡沫式人工腦膜(Foamagen)



**產品優勢:** 可**同時**完成腦膜**修補**及腦脊髓液**防漏**

**產品進度:** 已取得台灣上市許可，已在超過二十家以上的醫院銷售。

# 腦中風治療醫材





Source: <http://www.strokeassociation.org/STROKEORG/AboutStroke/TypesofStroke/>

美國每年80萬人/年發生; **50%失能**; **經濟損失650億美金**

**87%**為**缺血性**中風; 美國有**7億美金/年**市場規模

# 腦中風取栓導管系統



腦血管專用導管





腦中風血塊吸除幫浦

**技術優勢:** 可吸除**深層**腦中風**血塊**之**取栓**系統

**產品進度:** 導管及幫浦耗材取得美國產品上市許



可，已銷售到美國腦中風治療中心



# 持續合作開發





TWBM